Diabesity - novel molecular targets for obesity and type 2 diabetes
 
members  
Index  
Next Member  
Previous Member  
Dr Johannes Grosse Dr Heike Schauerte
Ingenium Pharmaceuticals AG
Fraunhoferstr
13, 82152
Martinsried/Munich
Germany
Phone: +49 89 8565 2392
E-mail
Dr Heike Schauerte
homepage
 

Research

Aim
Ingenium's Deductive Genomics® research program has identified a previously uncharacterized membrane protein (Chg-1) involved in obesity and the pathophysiologically linked disorder Type II diabetes.  Animals bearing the mutated form of this protein display significantly increased insulin and leptin sensitivity.  The well-known side effect of currently used pharmaceutical agents is increased insulin sensitivity, which is also seen in treatment of Type II diabetes.  In contrast to the human disease process, the Chg-1 animals are lean and resistant to high fat diet-induced obesity.  Blood serum parameters representing risk factors for vascular complications such as free fatty acids, triglycerides and glucose are significantly reduced.  Ingenium has accumulated to date encouraging data that explain these results through an increased sensitivity of leptin and insulin receptor signaling and other genetic factors related to obesity in peripheral tissues.

Ingenium will continue to advance research in the area to validate the importance of this novel biological pathway and exciting therapeutic principal and will seek to partner the project through co-development or other forms of collaboration.

 

Diabesity: Novel molecular targets for obesity and type 2 diabetes
   
  home | research | publications | members | events | about diabesity | press | links | contact us